SGH will process cord blood to develop and produce allogeneic chimeric antigen receptor (CAR) T-cells designed for cancer ...

Manipulating the immune system to treat cancer has generated phenomenal responses in some patients, including complete cures, ...

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.

Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative ...

The leading AL Amyloidosis Companies such as Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, ZENTALIS ...

DelveInsight's Advanced Therapy Medicinal Products Market Insights report provides the current and forecast market analysis, ...

Laboratories International announced an agreement with Singapore General Hospital SGH to provide Current Good Manufacturing ...

In a January 24 interview with the far-right-wing outlet Breitbart News, newly appointed CIA director John Ratcliffe stated ...

A couple facing a terminal multiple myeloma diagnosis finds renewed hope through innovative immunotherapy, transforming blood ...

Charles River to provide master cell banking and NGS testing services for SGH's cord blood derived allogeneic CAR-T cells.

Developing and commercialising a range of cell therapies in oncology.

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.